| 2026-08-11 | Deck | Absci Corporate Presentation, August 2026 |
| 2026-08-11 | Press release | Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results |
| 2026-08-11 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-11 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-14 | Press release | Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026 |
| 2026-06-24 | Press release | Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors |
| 2026-06-24 | Press release | Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolac |
| 2026-06-24 | 8-K | Form 8-K, Item 8.01 |
| 2026-06-24 | 8-K | Form 8-K, Item 1.01 |
| 2026-06-08 | Deck | Goldman Sachs 47th Annual Global Healthcare Conference Presentation |
| 2026-06-05 | 8-K | Form 8-K, Item 5.07 |
| 2026-06-02 | Deck | Jefferies Healthcare Conference Presentation |
| 2026-05-20 | Press release | Absci to Participate in Upcoming Investor Conferences |
| 2026-05-07 | Press release | Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results |
| 2026-05-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-07 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-04 | Press release | Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-04-23 | Press release | Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026 |
| 2026-04-22 | Proxy | Definitive proxy statement |
| 2026-04-08 | Press release | Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference |
| 2026-03-24 | Press release | Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic |
| 2026-03-24 | Press release | Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results |
| 2026-03-24 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-24 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-03-06 | 8-K | Form 8-K, Item 1.01 |
| 2026-02-24 | Press release | Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026 |
| 2026-01-14 | Deck | 44th Annual J.P. Morgan Healthcare Conference Presentation |
| 2026-01-14 | 8-K | Form 8-K, Item 8.01 |
| 2025-12-16 | Press release | Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
| Transcript | Earnings call transcript |
| 2025-12-11 | Deck | ABS-201 KOL Seminar Presentation |
| 2025-11-12 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-12 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-11-04 | 8-K | Form 8-K, Item 1.01 |
| 2025-10-15 | Press release | Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiatio |
| 2025-09-11 | Press release | Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD |
| 2025-08-12 | 8-K | Form 8-K/A, Item 2.02 results |
| 2025-08-12 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2025-07-25 | 8-K | Form 8-K, Item 1.01 |
| 2025-07-08 | 8-K | Form 8-K, Item 5.02 |